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Abstract For reversal of MDR1 gene-dependent multidrug re-
sistance (MDR), two small interfering RNA (siRNA) constructs
were designed to inhibit MDR1 expression by RNA interfer-
ence. SiRNA duplexes were used to treat human pancreatic
carcinoma (EPP85-181RDB) and gastric carcinoma (EPG85-
257RDB) cells. In both cellular systems, siRNAs could speci¢-
cally inhibit MDR1 expression up to 91% at the mRNA and
protein levels. Resistance against daunorubicin was decreased to
89% (EPP85-181RDB) or 58% (EPG85-257RDB). The data
indicate that this approach may be applicable to cancer patients
as a speci¢c means to reverse tumors with a P-glycoprotein-
dependent MDR phenotype back to a drug-sensitive one.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Resistance to antineoplastic drugs is the major reason why
chemotherapy-based treatment modalities of malignant tu-
mors may fail. Human cancer cells can exhibit a cross-resis-
tant phenotype against several unrelated drugs that di¡er
widely with respect to molecular structure and target speci¢c-
ity. This phenomenon has been termed multidrug resistance
(MDR) [1]. The ‘classical’ MDR phenotype is characterized
by a typical cross-resistance pattern against natural-product
anticancer agents, such as vinca alkaloids, anthracyclines, or
taxanes, and the reversibility by the calcium channel inhibitor
verapamil and cyclosporin A derivatives. The underlying
mechanism conferring this MDR phenotype is the cellular
overproduction of the MDR1 gene-encoded 170-kDa, mem-
brane-spanning P-glycoprotein (P-gp, P-170, PGY1, MDR1,
ABCB1) [2], a member of the superfamily of ABC (ATP bind-
ing cassette) transporters [3]. A disruption of P-gp-mediated
drug extrusion results in a re-sensitization of tumor cells to
treatment with antineoplastic agents, and thus may allow a
successful drug treatment of the multidrug-resistant cancer
cells [4].
Pharmacologically active compounds, designated MDR
modulators or chemosensitizers, may circumvent the ‘classical’
MDR phenotype by inhibiting the e¥ux pump activity of
P-gp [5]. One obstacle in applying MDR modulators arises
from their commonly occurring intrinsic toxicity at doses nec-
essary to be active, e.g. heart failure, hypotension, hyperbili-
rubinemia, and immunosuppression by cyclosporin A. Addi-
tionally, tumor cells can develop resistance against the
applied chemosensitizers, so-called tertiary resistance. Conse-
quently, it is necessary to develop alternative, less toxic and
more e⁄cient strategies to overcome MDR. Such an alterna-
tive procedure to circumvent P-gp-mediated MDR in cancer
cells is to prevent the biosynthesis of P-gp by selectively block-
ing the expression the P-gp-speci¢c MDR1 mRNA. This ap-
proach is aimed at increasing the e⁄ciency and speci¢city of
chemosensitization of multidrug-resistant cancer cells while at
the same time reducing toxicity and undesirable side e¡ects.
Thus, in previous studies, antisense oligonucleotides were
shown to modulate P-gp-dependent MDR [6,7]. Moreover,
hammerhead ribozymes were designed and successfully ap-
plied to decrease the expression level of the P-gp-encoding
MDR1 mRNA [8,9].
A novel means for speci¢c inhibition of a gene of interest is
the use of small interfering RNA (siRNA). These 21^25 nu-
cleotides (nt) long, double-stranded RNA (dsRNA) molecules
can direct degradation of eukaryotic mRNAs in a sequence-
speci¢c manner. This ubiquitous mechanism of gene regula-
tion in plants and animals was designated RNA interference
(RNAi) [10]. Physiologically, RNAi is initiated by the
dsRNA-speci¢c RNase III enzyme Dicer that is responsible
for the processing of long dsRNA into siRNA. These siRNAs
are incorporated into a protein complex that recognizes and
cleaves its target mRNAs [11]. Introduction of dsRNA into
mammalian cells does not result in e⁄cient Dicer-mediated
generation of siRNA and therefore does not induce RNAi
[12]. The requirement for Dicer in maturation of siRNAs
can be bypassed by introducing synthetic 21-nt siRNA du-
plexes that inhibit expression of transfected and endogenous
genes in a variety of mammalian cells [13].
In this study, two 21-nt siRNA duplexes against two re-
gions of the P-gp-encoding mRNA were designed for disrup-
tion of P-gp-mediated drug extrusion in a speci¢c manner and
re-sensitization of gastrointestinal tumor cells to treatment
with the antineoplastic agent daunorubicin. The ¢rst siRNA
molecule (MDR-A) was constructed according the recommen-
dations by others ([13,14], http://www.mpibpc.gwdg.de/abtei-
lungen/100/105/), the second siRNA (MDR-B) was designed
to be homologous to a well-assessable ribozyme cleavage site
analyzed in detail previously [8,15]. The biological activities of
both siRNA constructs were examined.
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2. Materials and methods
2.1. Cell lines and cell culture
Establishment and cell culture of the human gastric carcinoma cell
line EPG85-257P [16], and of the human pancreatic carcinoma cell
line EPP85-181P [17] was described in detail previously. In both cases,
‘classical’ multidrug-resistant, P-gp-positive derivatives, EPG85-
257RDB [18] and EPP85-181RDB [17], were established by in vitro
exposure to daunorubicin (Farmitalia Carlo Erba, Freiburg, Ger-
many). In order to ensure maintenance of the ‘classical’ MDR phe-
notype, cell culture medium for the P-gp-expressing lines EPG85-
257RDB and EPP85-181RDB was supplemented with 5.09 WM (2.5
Wg/ml) daunorubicin.
2.2. Cytotoxicity assay for cell survival
Chemoresistance was tested using a proliferation assay based on
sulforhodamine B (SRB), a protein-binding reagent [19], as described
previously [17,20]. Brie£y, in each experiment 1500 cells per well were
seeded in 96-well plates and daunorubicin was added in dilution series
in triplicate wells. After 4 days, incubation was terminated by replac-
ing the medium with 10% trichloroacetic acid, followed by incubation
at 4‡C for 1 h. Subsequently, the plates were washed ¢ve times with
water and stained by adding 100 Wl 0.4% SRB (Sigma, St. Louis, MO,
USA) in 1% acetic acid for 10 min at room temperature. Unbound
dye was eliminated by washing the plates ¢ve times with 1% acetic
acid. After air-drying and re-solubilization of the protein-bound dye
in 10 mM Tris^HCl (pH 8.0), absorbance was read at 562 nm against
a background at 690 nm. To determine the IC50 values, the absor-
bance di¡erence of control cells without drug was set at 1. A dose^
response curve was plotted using the Prism software (GraphPad Soft-
ware, San Diego, CA, USA), and IC50 values were calculated from
multiple (at least three) independent experiments for each cell line.
Cytotoxicity analyses were performed 48 h after siRNA treatment
of MDR cells. Survival data of siRNA-treated cells were evaluated
for statistical signi¢cance by the two-sided t-test.
2.3. siRNA design
Two di¡erent P-gp-speci¢c siRNA duplexes were designed to be
homologous to the P-gp-encoding MDR1 mRNA consensus sequence
(GenBank accession number NM_000927). Both 21-nt siRNAs con-
tained 3P-dTdT extensions and were commercially obtained from
Dharmacon (Lafayette, CO, USA). The target sequence of the ¢rst
siRNA molecule, MDR-A (5P-AAG AAG GAA AAG AAA CCA
ACU-3P), homologous to nt 503^523 of the MDR1 mRNA sequence
NM_000927, was chosen according the recommendations by others
([13,14], http://www.mpibpc.gwdg.de/abteilungen/100/105/). The sec-
ond siRNA, MDR-B (5P-AAA AUG UUG UCU GGA CAA
GCA-3P), homologous to nt 3050^3070, was constructed against the
well-assessable hammerhead ribozyme cleavage GUC site at nt 3058^
3060 that was analyzed in detail previously [8,15].
2.4. Transfection with siRNAs
For transfection of MDR-A and MDR-B, either dsRNA or as
control single-stranded oligonucleotide molecules were handled ac-
cording the recommended procedure ([13,14], http://www.mpibpc.
gwdg.de/abteilungen/100/105/) by using OligofectAMINE Reagent
(Gibco BRL, Gaithersburg, MD, USA) for forming liposomes. Before
starting transfection experiments with MDR-A and MDR-B, a
dsRNA sequence for silencing the lamin A/C mRNA was used for
optimization of the RNAi application as recommended ([13,14],
http://www.mpibpc.gwdg.de/abteilungen/100/105/).
2.5. Northern blot analysis
The amount of the P-gp-encoding MDR1 mRNA was determined
by Northern blot analysis applying standard procedures as described
previously [17,20]. In brief, total cellular RNA was prepared using a
RNeasy Mini Kit (Qiagen). 10 Wg RNA was separated on 1% agarose-
formaldehyde gels and transferred onto a Hybond-Nþ membrane
(Amersham, Aylesbury, UK). Blots were hybridized with 25 ng of a
557-bp MDR1 cDNA fragment labeled with [32P]dCTP by random
primed labeling (Amersham). The hybridization probe was generated
by reverse transcription polymerase chain reaction (RT-PCR) using a
cDNA template obtained by reverse transcription of total RNA pre-
pared from the cell line EPP85-181RDB using the SuperScript Pre-
ampli¢cation System (Gibco BRL). Sequence-speci¢c oligonucleotide
primers were designed after alignment with the P-gp-encoding nucleic
acids sequence NM_000927. Oligodeoxynucleotide primers used for
ampli¢cation were PGP-fw: 5P-GCC CTT GGA ATT ATT TCT
TT-3P and PGP-rev: 5P-TGG GTG AAG GAA AAT GTA AT-3P.
Subsequently, the PCR product was cloned into the pCR2.1 vector
using an Original TA Cloning Kit (Invitrogen, San Diego, CA, USA).
The identity of the PCR product was con¢rmed by dye terminator
sequencing using an ABI-373 sequencer (Perkin Elmer). As control for
equal RNA loading the membranes were stripped and rehybridized
with a fructose-bisphosphate aldolase (aldolase)-encoding cDNA
probe, prepared as described in Section 2.6.
2.6. Quantitative RT-PCR
For quantitative mRNA expression analysis, real-time RT-PCR
was carried out with total RNA (see above) prepared 48 h after
siRNA treatment using a LightCycler instrument (Roche Diagnostics,
Mannheim, Germany). Oligodeoxynucleotide primers used for ampli-
¢cation were PGP-fw and PGP-rev (see above) and as control Ald-fw:
5P-ATC CTG GCT GCA GAT GAG TC-3P, Ald-rev: 5P-GCC CTT
GTC TAC CTT GAT GC-3P yielding an expected ampli¢cation prod-
uct of 249 bp speci¢c for a housekeeping gene encoding aldolase
(GenBank accession number NM_000034). Likewise, the identity of
the aldolase-speci¢c PCR product was con¢rmed by sequencing. Re-
verse transcription was performed with SuperScript II enzyme (Gibco
BRL) using arbitrary hexamers. Ampli¢cation products were detected
on-line via intercalation of the £uorescent dye SYBR green (Light-
Cycler-FastStart DNA Master SYBR Green I kit, Roche Diagnos-
tics). Cycling conditions for P-gp (aldolase) were as follows: initial
enzyme activation at 95‡C for 10 min, followed by 45 cycles at 94‡C
(95‡C) for 15 s, 50‡C (54‡C) for 5 s and 72‡C for 10 s. All cycling
reactions were performed in the presence of 4 WM MgCl2. Gene-spe-
ci¢c £uorescence was measured at 84‡C (86‡C) and con¢rmed by
melting curve analysis. For quanti¢cation, samples were normalized
against the expression of the aldolase-encoding mRNA. RNA expres-
sion data of siRNA-treated cells were evaluated for statistical signi¢-
cance by the two-sided t-test.
2.7. Western blot analysis
For detection of P-gp, membrane protein extracts were prepared as
described previously [17,20]. Samples of 10 Wg of membrane proteins
each were diluted with sample bu¡er and separated on 4% stacking
and 7.5% resolving sodium dodecyl sulfate^polyacrylamide gel. Sepa-
rated proteins were transferred to a 0.2 Wm cellulose nitrate membrane
(Schleicher and Schuell, Dassel, Germany). To avoid unspeci¢c bind-
ing, the ¢lters were incubated in 5% skim milk, 0.05% Tween 20 in
TBS overnight. Subsequently, ¢lters were incubated with mouse
monoclonal antibodies (mAbs) C219 (Alexis, San Diego, CA, USA)
directed against human P-gp diluted in 1% skim milk in 1UTBST (20
mM Tris^HCl; 137 mM NaCl; 0.05% Tween 20; pH 7.5) (1:100) for
2 h and, afterwards, with peroxidase-conjugated mouse anti-rabbit
IgG (1:10 000) (Sigma, St. Louis, MO, USA; #A-1949). As control
for equivalent protein loading, the ¢lters were simultaneously incuba-
ted with a mouse mAb directed against actin (Chemicon, Temecula,
CA, USA; #MAB 1501R) diluted 1:3000. The protein^antibody com-
plexes were visualized by chemoluminescence (ECL system, Amer-
sham, Buckinghamshire, UK).
3. Results
3.1. Decrease of the P-gp-encoding mRNA expression using
siRNAs
Two di¡erent siRNA constructs, MDR-A and MDR-B,
were used to decrease the expression of the P-gp-encoding
MDR1 mRNA in the human multidrug-resistant gastric and
pancreatic carcinoma cell lines EPG85-257RDB and EPP85-
181RDB, respectively. Northern blot analyses demonstrated
that both siRNAs MDR-A (Fig. 1B) and MDR-B (Fig. 1D)
decreased the MDR1 mRNA expression level in the multi-
drug-resistant gastric carcinoma cell line EPG85-257RDB in
a time-dependent manner. Using both siRNAs, after 1 day of
siRNA transfection only a weak MDR1 mRNA-speci¢c sig-
nal could be detected. Following 3 and 5 days the MDR1
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mRNA expression level tardily increases, reaching the original
mRNA expression value after 7 days.
In the case of multidrug-resistant pancreatic carcinoma
cells, Northern blot experiments revealed that the gene-silenc-
ing e¡ects of both siRNA molecules were much more pro-
nounced than in the gastric carcinoma model. By treatment
with MDR-A (Fig. 1F) or MDR-B (Fig. 1H), the expression
level of the MDR1 mRNA was reduced to the point at which
it could no longer be detected up to 3 days after siRNA
transfection. After that time period the MDR1 mRNA ex-
pression started to increase and reached the original mRNA
expression level after 10 days.
Using the conventional designed siRNA molecule MDR-A,
none of the controls, MDR-A-speci¢c single-stranded sense or
antisense RNA oligonucleotides, medium in the absence of
any supplements, and medium with transfection reagent,
showed any e¡ects on the MDR1 mRNA expression level
after 48 h in Northern blot experiments (Fig. 1B,F). In con-
trast to this observation, the second single-stranded antisense
MDR-B RNA oligonucleotide directed against a well-assess-
able hammerhead ribozyme cleavage side showed slight gene-
silencing e¡ects on MDR1 mRNA expression in multidrug-
resistant gastric carcinoma as well as in pancreatic carcinoma
cells (Fig. 1D,H).
To obtain quantitative MDR1 mRNA expression values,
quantitative real-time RT-PCR experiments were performed
after 48 h of treatment with siRNA constructs or controls.
These quantitative MDR1 mRNA expression values con-
¢rmed the data obtained by Northern blot analyzes, but re-
vealed some more detailed information.
As shown in Fig. 2A, the multidrug-resistant gastric carci-
noma cell line EPG85-257RDB exhibited a 933-fold overex-
pression of MDR1 mRNA when compared to the drug-sensi-
tive, parental variant EPG85-257P. Treatment with MDR-A
decreased the MDR1 mRNA level to 13%, treatment with
MDR-B decreased it to 26% of the original MDR1 mRNA
expression value, i.e. 87% and 74% gene-silencing activity in
gastric carcinoma cells. In the case of MDR-A, the single-
stranded MDR-A sense oligonucleotide and the single-
stranded MDR-A antisense oligonucleotide showed no rele-
vant e¡ects on MDR1 mRNA expression. In contrast, both
single-stranded MDR-B oligonucleotides distinctly decreased
Fig. 1. Characterization of siRNA-mediated decrease of MDR1 mRNA expression and cellular P-gp content in human gastric carcinoma and
pancreatic carcinoma cells. A: Western blot analysis of cell membranous P-gp content following MDR-A siRNA exposure in gastric carcinoma
cells. B: Northern blot analysis depicting MDR1 mRNA expression during silencing using the MDR-A siRNA construct in gastric carcinoma
cells. C: Western blot following MDR-B exposure in gastric carcinoma cells. D: Northern blot following MDR-B treatment in gastric carcino-
ma cells. E: Western blot following MDR-A exposure in pancreatic carcinoma cells. F: Northern blot using MDR-A in pancreatic carcinoma
cells. G: Western blot following MDR-B exposure in pancreatic carcinoma cells. H: Northern blot after MDR-B treatment in pancreatic carci-
noma cells. In each case, Northern blot membranes were stripped and reprobed for aldolase-encoding mRNA as loading control. As control
for equivalent protein loading, Western blot membranes were simultaneously incubated with an actin-speci¢c mAb. EPG85-257RDB, multi-
drug-resistant gastric carcinoma cells; EPG85-257P, drug-sensitive gastric carcinoma cells; EPP85-181RDB, multidrug-resistant pancreatic carci-
noma cells; EPP85-181P, drug-sensitive pancreatic carcinoma cells; MDR-A siRNA, double-stranded biologically active siRNA; MDR-A sense,
single-stranded MDR-A RNA in sense orientation; MDR-A antisense, single-stranded MDR-A RNA in antisense orientation; MDR-B siRNA,
double-stranded biologically active siRNA; MDR-B sense, single-stranded MDR-B RNA in sense orientation; MDR-B antisense, single-
stranded MDR-B RNA in antisense orientation; control 1, medium; control 2, medium with transfection reagent.
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the MDR1 mRNA expression, especially the MDR-B anti-
sense oligonucleotide showed a similar gene-silencing activity
like the complete siRNA construct.
The multidrug-resistant pancreatic carcinoma cell line
EPP85-181RDB showed a 1088-fold MDR1 mRNA overex-
pression in comparison to the non-resistant counterpart
EPP85-181P (Fig. 2B). In this model system, MDR-A de-
creased the MDR1 mRNA expression level likewise to 13%,
MDR-B even to 9% of the initial value. In other words, in
pancreatic carcinoma cells 87% and 91% gene-silencing activ-
ity could be demonstrated. Both single-stranded MDR-A con-
trol oligonucleotides showed similar slight e¡ects on MDR1
mRNA expression, i.e. decrease to 61% (MDR-A sense) or
62% (MDR-A antisense). The single-stranded MDR-B sense
oligonucleotide showed negligible activity, whereas a distinct
MDR1 mRNA expression-inhibiting activity to 30% could be
observed by applying the single-stranded MDR-B antisense
oligonucleotide.
As determined by quantitative real-time RT-PCR, both
drug-sensitive, parental cell lines showed a very low compa-
rable basic MDR1 mRNA expression that could not be de-
tected by the less sensitive Northern blot procedure. The low-
est MDR1/aldolase mRNA expression ratio was measured in
the drug-sensitive pancreatic carcinoma cell line EPP85-181P;
this was set at 1. The parental gastric carcinoma cell line
EPG85-257P showed a slightly increased MDR1 mRNA ex-
pression value of 1.8-fold when compared to the pancreatic
carcinoma line EPP85-181P. Thus, relative MDR1 mRNA
expression values were normalized against the pancreatic car-
cinoma cell line. As a consequence, both multidrug-resistant
cancer cell lines showed MDR1 mRNA overexpression in a
similar range, where a slightly enhanced value could be mea-
sured in the multidrug-resistant gastric carcinoma line, i.e.
1571-fold overexpression in gastric cancer cells instead of
1088-fold in pancreatic carcinoma-derived MDR cells.
3.2. Knockdown of P-gp on protein level by siRNAs
Western blot experiments demonstrated that both siRNA
constructs decreased the cellular P-gp content in both multi-
drug-resistant gastrointestinal tumor cell models. This reduc-
Fig. 2. Analysis of siRNA-mediated silencing of MDR1 mRNA expression determined by quantitative real-time RT-PCR and characterization
of MDR reversal by depicting the resistance against daunorubicin as determined by IC50 values in human gastric carcinoma and pancreatic car-
cinoma cells. All experiments were performed 48 h after treatment with siRNA molecules. A: Relative MDR1 mRNA expression level normal-
ized against aldolase mRNA expression in gastric carcinoma cells. The MDR1/aldolase expression ratio in drug-sensitive EPG85-257P cells was
set at 1. B: Relative MDR1 mRNA expression level normalized against aldolase mRNA expression in pancreatic carcinoma cells. The MDR1/
aldolase mRNA expression ratio in drug-sensitive EPP85-181P cells was set at 1. C: Relative resistance against daunorubicin in gastric carcino-
ma cells. Resistance value in drug-sensitive, parental EPG85-257P cells was set at 1. D: Relative resistance against daunorubicin in pancreatic
carcinoma cells. Resistance value in drug-sensitive EPG85-257P cells was set at 1. EPG85-257RDB, multidrug-resistant gastric carcinoma cells;
EPG85-257P, drug-sensitive gastric carcinoma cells; EPP85-181RDB, multidrug-resistant pancreatic carcinoma cells; EPP85-181P, drug-sensitive
pancreatic carcinoma cells; MDR-A siRNA, double-stranded biologically active siRNA; MDR-A sense, single-stranded MDR-A RNA in sense
orientation; MDR-A antisense, single-stranded MDR-A RNA in antisense orientation; MDR-B siRNA, double-stranded biologically active
siRNA; MDR-B sense, single-stranded MDR-B RNA in sense orientation; MDR-B antisense, single-stranded MDR-B RNA in antisense orien-
tation. The relative expression values are means of at least three independent experiments in triplicate, error bars show S.D. Treatment of mul-
tidrug-resistant gastrointestinal cancer cells statistically signi¢cantly decreased the MDR1 mRNA expression level and the resistance against
daunorubicin: n.s., non-signi¢cant di¡erence to the multidrug-resistant cell line; *P6 0.05; **P6 0.01; ***P6 0.001.
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tion of transmembrane transport protein concentration was
time-slipped in relation to the decrease in MDR1 mRNA ex-
pression. In MDR gastric carcinoma cells as well as in pan-
creatic carcinoma MDR cells the peak of protein reduction
was reached after 3^5 days using MDR-A siRNA (Fig. 1A,E)
or MDR-B siRNA (Fig. 1C,G). As shown at the mRNA level,
the biological activity of both siRNAs was more pronounced
in the pancreatic carcinoma model EPP85-181RDB. The
Western blot analyses showed that in none of the cases the
cellular P-gp content could be reduced completely. As dem-
onstrated at the mRNA level, single-stranded MDR-B anti-
sense oligonucleotides also showed a biological activity at the
protein level, whereas no e¡ect could be observed by any
other of the controls.
3.3. Reversal of the drug-resistant phenotype by siRNAs
The siRNA-mediated reversal of the multidrug-resistant
phenotype was assessed by comparison of the IC50 values
determined by a cell proliferation assay in siRNA-treated tu-
mor cells and controls. Cytotoxicity experiments were per-
formed 48 h after treatment with siRNA molecules. In both
gastrointestinal tumor cell systems, MDR-B siRNA showed a
slightly enhanced chemosensitizing activity compared to
MDR-A (Fig. 2C,D). In the gastric carcinoma system, both
RNAi constructs showed less chemosensitizing activity than in
the pancreatic carcinoma model. MDR-A siRNA decreased
the resistance factor from 595-fold to 310-fold (decrease to
52% of the initial value, i.e. 48% reversal ; P6 0.01), MDR-
B siRNA decreased the resistance against daunorubicin from
595-fold to 250-fold (decrease to 42% of the initial value, i.e.
58% reversal ; P6 0.001) in EPG85-257RDB gastric carcino-
ma cells. The multidrug-resistant phenotype of the pancreatic
carcinoma cell line EPP85-181RDB was reversed from 538-
fold to 68-fold (decrease to 13% of the initial value, i.e. 87%
reversal ; P6 0.001) by MDR-A siRNA, and from 538-fold to
57-fold (decrease to 11% of the initial value, i.e. 89% reversal ;
P6 0.001) by MDR-B siRNA. The single-stranded MDR-B
sense and both single-stranded MDR-A control oligonucleo-
tides showed no MDR-modulating e¡ects, whereas a distinct
chemosensitizing activity of the MDR-B antisense oligonu-
cleotide could be observed in both multidrug-resistant gastro-
intestinal tumor cell lines, i.e. 32% reversal in EPG85-
257RDB (P6 0.05) and 52% reversal in EPP85-181RDB
(P6 0.01).
4. Discussion
Experimental endeavors to overcome the obstacles in the
use of conventional MDR modulators resulted in the develop-
ment of antisense and antigene strategies. These included the
application of oligonucleotides [6,7] and hammerhead ribo-
zymes [8,9] directed against the P-gp-encoding MDR1
mRNA and against the transcripts of alternative genes encod-
ing MDR-mediating factors, such as LRP [21], MRP1 [22],
MRP2 [23], or BCRP [24,25]. In the present study, the mod-
ulation of the P-gp-mediated ‘classical’ MDR phenotype was
demonstrated by an alternative, novel gene therapeutic means,
i.e. by RNAi triggered by synthetic siRNA molecules homol-
ogous to the MDR1 mRNA. Both of the applied anti-MDR1
siRNA constructs, MDR-A designed according conventional
recommendations ([13,14], http://www.mpibpc.gwdg.de/abtei-
lungen/100/105/) and MDR-B constructed to be homologous
to a well-assessable hammerhead ribozyme cleavage site [8,15],
decreased the MDR1 mRNA expression level in a speci¢c
manner in two di¡erent multidrug-resistant cell systems de-
rived from gastric carcinoma or pancreatic carcinoma. As a
consequence, the cellular amount of P-gp was decreased and
both multidrug-resistant gastrointestinal carcinoma cell lines
became concomitantly sensitive to anthracycline treatment, a
hallmark of the P-gp-mediated MDR phenotype.
Both siRNA constructs showed a more pronounced MDR1
gene-silencing activity in MDR pancreatic carcinoma cells at
the mRNA as well as the protein level. Moreover, these e¡ects
were accompanied by a more e¡ective MDR-reversing activity
in the MDR pancreatic carcinoma cell model. These observa-
tions might be explained by the more elevated MDR1 mRNA
expression level in the multidrug-resistant gastric carcinoma
cell line EPG85-257RDB and/or by tissue-speci¢c features,
e.g. variable cellular siRNA molecule uptake or di¡erences
in the e¡ectiveness of the cellular RNAi mechanisms leading
to mRNA degradation in discriminative cell systems.
In both gastrointestinal MDR models, the chemosensitizing
activity of the MDR-B siRNA construct was more pro-
nounced. This e¡ect might be explained by an additional anti-
sense e¡ect of the single-stranded MDR-B antisense oligonu-
cleotide that could be observed in both cellular systems. The
MDR-reversing e¡ect of the single-stranded MDR-B anti-
sense oligonucleotide was accompanied by a distinct biologi-
cal e¡ect at the mRNA (Northern blot, real-time RT-PCR)
and protein (Western blot) levels. Real-time RT-PCR quanti-
fying of the P-gp-speci¢c mRNA even demonstrated a similar
MDR1 gene-silencing e¡ect of the single-stranded MDR-B
antisense oligonucleotide like the complete double-stranded
siRNA construct. This distinct putative antisense activity
might be explained by the well-assessable secondary structure
of the MDR1 mRNA in this region that was demonstrated by
ribozyme cleavage experiments previously [15].
The more pronounced gene-silencing e¡ects of the MDR-B
siRNA construct are in contradiction to the observations
made so far by others who concluded that compared to anti-
sense or ribozyme technology, the secondary structure of
siRNA target mRNAs does not appear to have a strong e¡ect
on gene silencing [14]. Thus, in future experiments the second-
ary structure of the target molecule should be taken into con-
sideration. Moreover, the design of biologically active siRNA
molecules can be improved by the elaborate experiences in the
use of antisense oligonucleotides and hammerhead ribozymes
obtained previously. Whether the more pronounced gene-si-
lencing e¡ect of MDR-B is indeed the result of an additional
antisense e¡ect or of a more e¡ective RNAi e¡ect at this
RNA secondary structure remains open. However, in a po-
tential therapeutic application the more biologically e¡ective
siRNA construct should be chosen.
The ‘classical’ MDR phenotype could be reversed 48% by
MDR-A and 58% by MDR-B in MDR gastric cancer cells,
and 87% by MDR-A and 89% by MDR-B in the pancreatic
carcinoma MDR cell line EPP85-181RDB. Thus, the chemo-
sensitizing e¡ects of these transiently added siRNA molecules
are in the same range that could be found in cells stably
transfected with expression vector constructs encoding ham-
merhead ribozymes directed against alternative MDR factors
[8,9,25]. Thus, more pronounced MDR-modulating e¡ects of
both anti-MDR1 mRNA siRNA constructs could be expected
by stable transfection of the multidrug-resistant cell lines us-
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ing siRNA-containing expression vectors. Moreover, it is im-
portant to note that the MDR cell models used are extremely
highly resistant and exhibit an enormously enhanced MDR1
mRNA expression level. In the clinical situation, a two-fold or
three-fold increased resistance level is already su⁄cient to in-
hibit a successful antineoplastic drug-based cancer therapy.
Thus, for the potential treatment of cancer patients, even a
transient application of anti-MDR1 mRNA siRNA constructs
might be an e¡ective tool for the reversal of drug resistance.
However, for reversal of clinical MDR the use of synthetic
siRNAs, as opposed to siRNAs expressed from an expression
vector system such as recently described [26], possibly may
have advantages. Chemically synthesized siRNAs obviate
the need to address technical and ethical problems raised by
the use of expression vectors, especially potential retrovirus-
or adenovirus-based siRNA delivery systems. Furthermore,
synthetic siRNAs are more suitable for combination thera-
pies. It would be easier to use chemically synthesized siRNAs
simultaneously in combination against the transcripts of var-
ious MDR-associated genes, e.g. alternative ABC transporter-
encoding genes or genes encoding apoptosis- and cell cycle-
regulating factors. Moreover, such a combination therapy
could include siRNAs directed against additional targets,
such as oncogenes or angiogenic factors.
The mechanism of RNAi-triggered mRNA destruction
represents a novel and powerful tool for the application in
gene therapy of cancer. Oncogene products and other malig-
nancy-associated gene transcripts, e.g. drug resistance-mediat-
ing molecules, are the potential targets for such a gene ther-
apeutic strategy. A prerequisite for a therapeutic application
of siRNAs is that the targeted cancer cells contain a func-
tional RNAi mechanism to bind to siRNAs and mediate
mRNA degradation. So far only rare reports are available
in which siRNAs were used for treatment of neoplastic cells,
e.g. speci¢c inhibition of the bcr-abl oncogene which causes
chronic myeloid and bcr-abl-positive acute lymphoblastic leu-
kemia [27], or the selective deletion of point-mutated p53 in
cells expressing mutated and non-mutated p53, resulting in a
restoration of the wild type protein function [28].
At the time of submission, this work presented the ¢rst
evidence for silencing MDR-associated genes by siRNA in
multidrug-resistant cancer cells. The data demonstrated the
proof of principle that endogenous siRNAs can be applied
to activate RNAi-mediated degradation of the MDR-associ-
ated MDR1 mRNA in targeted cancer cells. However, very
recently siRNA-based suppression of MDR1 mRNA expres-
sion was reported in multidrug-resistant breast cancer and
ovarian carcinoma cell lines [29]. That study applied a siRNA
duplex similar to the MDR-A siRNA construct used in this
study, i.e. the siRNA sequence targeted the MDR1 mRNA
corresponding to nt 508^528 of the consensus sequence
NM_000927 instead of nt 503^523 (MDR-A). Due to di¡er-
ences in the experimental procedures the e¡ectiveness of both
constructs cannot be compared directly. However, by apply-
ing a clonogenic assay instead of a proliferation assay, the
anthracycline (doxorubicin) resistance-reversing activity of
the nt 508^528 siRNA duplex was 80% in the case of 61-
fold doxorubicin-resistant ovarian carcinoma cells, and 92%
in the case of 300-fold doxorubicin-resistant breast cancer
cells in comparison to a RNA oligonucleotide-free transfec-
tion reagent-containing control.
The utilized anti-MDR1 mRNA siRNA constructs used in
this study not only appear to be e¡ective laboratory tools for
the investigation of MDR, but also have implications for the
prevention, reversal of MDR, and prolonging disease-free
survival in certain cases by gene therapeutic approaches.
Although for clinical use additional problems have to be
solved, e.g. delivery of siRNAs, the data presented here dem-
onstrate that a new speci¢c means to reverse the P-gp-depen-
dent MDR phenotype is now available.
Additional problems for clinical P-gp inhibition by anti-
MDR1 siRNAs may arise by the physiological expression of
this ABC transporter in several epithelial and endothelial
cells. For example, P-gp is strongly expressed in the luminal
membranes of the endothelium of blood vessels in the brain
[30] suggesting that P-gp plays an important role in the
blood^brain barrier and thus is crucial for limiting the poten-
tial neurotoxicity of many anticancer drugs. Thus, in the clin-
ical situation it may be necessary that the application of P-gp-
inhibiting siRNAs should be restricted to P-gp-expressing can-
cer cells. One promising strategy for cancer cell-limited deliv-
ery of anti-MDR1 siRNAs would be the development of vec-
tor systems speci¢c for multidrug-resistant cancer cells, such
as mutant adenoviral vectors e⁄ciently and selectively repli-
cating in multidrug-resistant cells [31].
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